Eli Lilly's 340B Policy Shift: Impact on Hospital Networks and Pharma Strategy
Decision brief
Answer first · skim in under a minute
Eli Lilly's recent five-day ultimatum for hospitals to submit 340B claims data highlights a strategic shift in how pharmaceutical companies are managing compliance and discounts. This move places increased burden on hospital networks and signals a broader trend in the industry.
Eli Lilly’s 340B strategy now centers on limiting where discounted product can ship and demanding claims-level visibility. The company’s SEC filings describe a Contract Pharmacy Limited Distribution System that hospital networks must navigate alongside HRSA’s contract pharmacy and duplicate-discount rules—raising compliance cost and legal risk for both sides.
Contents9 sections
Key Takeaways
- Lilly’s 10-K describes a Contract Pharmacy Limited Distribution System that generally confines 340B pricing to in-house channels or a single designated contract pharmacy when no in-house outpatient pharmacy exists.
- Claims-level data is ordinarily required for contract pharmacy arrangements under that system.
- HRSA’s contract pharmacy guidance still requires OPAIS registration and duplicate-discount controls.
- Multiple HHS/HRSA lawsuits remain pending; outcomes could reshape manufacturer distribution rules industry-wide.
What does Eli Lilly disclose about its 340B distribution limits?
In its Form 10-K for the year ended 31 December 2025, Lilly states it implemented a Contract Pharmacy Limited Distribution System for 340B sales. Distribution of 340B-priced product is generally limited to covered entities and their child sites, or—if the covered entity lacks an in-house outpatient pharmacy—to one designated contract pharmacy under a bill-to/ship-to arrangement.
The filing adds that claims-level data is ordinarily required for any contract pharmacy, with limited exceptions such as certain “penny priced” insulin products when discounts are passed through at the point of sale. Read the primary text in Lilly’s FY2025 Form 10-K on SEC.gov.
How do HRSA contract pharmacy rules frame hospital obligations?
Separately from manufacturer policies, HRSA’s contract pharmacy page explains that covered entities may contract with one or more pharmacies, must register those pharmacies in the 340B OPAIS system, and remain responsible for compliance. Duplicate discounts are prohibited under the 340B statute; entities must manage Medicaid carve-in versus carve-out status.
HRSA’s duplicate discount guidance underscores manufacturer and federal audit exposure if mechanisms fail. Hospital networks therefore face parallel tracks: federal program integrity rules and manufacturer-specific data or shipping conditions.
Why are claims data and litigation strategically linked?
Lilly’s Q1 2026 Form 10-Q recounts litigation dating to January 2021 challenging HHS’s December 2020 advisory opinion on contract pharmacies and ADR regulations, plus related HRSA correspondence asserting that Lilly’s contract pharmacy policy violated the 340B statute. Appeals and ADR petitions remain part of the disclosed risk set on SEC Form 10-Q.
The same 10-K discusses a November 2024 suit over a proposed cash replenishment model versus product replenishment; a May 2025 D.C. district court decision sided with HRSA on preapproval requirements, which Lilly appealed. Strategy teams should treat court calendars as catalysts equal to policy memos.
What does this mean for hospital networks and peer manufacturers?
For IDNs and disproportionate-share hospitals, limited contract pharmacy networks and data submission requirements raise IT and pharmacy operations cost. For manufacturers, the playbook is clear: constrain diversion risk, demand claims visibility, and litigate statutory interpretation when HHS guidance conflicts with internal controls.
- Peer manufacturers watch whether courts bless limited distribution systems.
- Payers and PBMs sit adjacent: 340B economics affect outpatient pharmacy margins and specialty dispensing.
- State statutes that restrict manufacturer data conditions can create geographic carve-outs that fragment national policy.
What remains unproven or unresolved?
SEC filings confirm Lilly’s stated system and litigation posture; they do not, by themselves, quantify how many covered entities lost 340B eligibility on any given enforcement date. Secondary press figures about short compliance windows or headcounts should not be treated as audited facts until they appear in primary filings, court dockets or HRSA notices. Final program rules could still shift after appellate decisions.
Related NovaPharma coverage
- Pharma Pulse: 340B Uncertainty, Drug Shortages, and Wegovy
- Eli Lilly Gene Therapy Cholesterol Deals
- Lilly Vaccine Research and Biotech Buyouts
Frequently Asked Questions
What is Eli Lilly’s Contract Pharmacy Limited Distribution System?
Per Lilly’s FY2025 Form 10-K, the system generally limits 340B-priced product to covered entities and child sites, or—if there is no in-house outpatient pharmacy—to a single designated contract pharmacy, with claims-level data ordinarily required for contract pharmacy arrangements.
How does HRSA describe contract pharmacy rules?
HRSA states that a 340B covered entity may contract with pharmacies to dispense 340B drugs to eligible patients, must register contract pharmacies in OPAIS, and must prevent duplicate discounts—including Medicaid carve-in/carve-out rules.
Is Lilly’s 340B approach still in litigation?
Yes. Lilly’s SEC disclosures describe ongoing litigation with HHS/HRSA over contract pharmacy obligations and related ADR processes, plus a separate dispute over a proposed cash replenishment model that a D.C. district court said required HRSA preapproval.
Primary Sources
Eli Lilly pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
